Helix Acquisition Corp. II's Milestone: SEC Approves Registration for BridgeBio Oncology Merger

Deal News | Jul 11, 2025 | Globenewswire

Helix Acquisition Corp. II, a special purpose acquisition company (SPAC) sponsored by Cormorant Asset Management, and TheRas, Inc., doing business as BridgeBio Oncology Therapeutics, have announced the effectiveness of their registration statement regarding a proposed business combination. The U.S. Securities and Exchange Commission has declared the registration effective, paving the way for a merger between Helix and BridgeBio's clinical-stage biopharmaceutical segment. Shareholders of Helix are set to vote on the proposal in an extraordinary general meeting scheduled for August 4, 2025. The merger aims to leverage BridgeBio's pipeline of small molecule therapeutics targeting RAS and PI3K malignancies. Upon closing, the consolidated entity will be named BridgeBio Oncology Therapeutics (PubCo). The merger's success is contingent on shareholder approval and satisfaction of other closing conditions, with plans to finalize in August 2025.

Sectors

Biotechnology
Finance and Investment

Geography

United States – The headquarters of Helix Acquisition Corp. II is in Boston, Massachusetts, and the operations of the SEC mentioned indicate the U.S. relevance.

Industry

Biotechnology – This industry is relevant as the article involves BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company focusing on novel cancer treatments.
Finance and Investment – The article discusses a business combination involving a SPAC, a financial vehicle used for mergers and acquisitions, indicating the relevance of this industry.

Financials

$184 million – Funds raised by Helix Acquisition Corp. II during its initial public offering.

Participants

Name	Role	Type	Description
Helix Acquisition Corp. II	Acquirer	Company	A SPAC formed to merge with or acquire target companies, backed by Cormorant Asset Management.
BridgeBio Oncology Therapeutics	Target	Company	A clinical-stage biopharmaceutical company developing therapies for RAS and PI3K malignancies.
Cormorant Asset Management	Sponsor	Company	The sponsor of Helix Acquisition Corp. II, facilitating the SPAC's financial backing.
U.S. Securities and Exchange Commission	Regulatory Body	Government	The SEC has declared the registration statement effective, allowing the business combination to proceed.